[1] SIEGEL R L,MILLER K D,WAGLE N S,et al.Cancer statistics,2023[J].CA Cancer J Clin,2023,73(1):17-48.
[2] GAONA-LUVIANO P,MEDINA-GAONA L A,MAGAÑA-PÉREZ K.Epidemiology of ovarian cancer[J].Chin Clin Oncol,2020,9(4):47-52.
[3] 栗宝华,赵丽嫣.激素和上皮性卵巢癌研究新进展[J].中国妇产科临床杂志,2003,4(3):223-226.
[4] 董倩,龙潇冉,狄文.长链非编码RNA及相关微小RNA在卵巢癌中的研究进展[J].国际妇产科学杂志,2020,47(3):327-331,339.
[5] YANG L,XIE H J,LI Y Y,et al.Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer(Review)[J].Oncol Rep,2022,47(4):82-91.
[6] 曹美婷,耿海燕,贾海霞,等.新辅助化疗结合手术治疗晚期卵巢癌的近期疗效及远期疗效观察[J].肿瘤药学,2022,12(4):508-513.
[7] ZHANG W,SU X,LI S,et al.Low serum exosomal miR-484 expression predicts unfavorable prognosis in ovarian cancer[J].Cancer Biomark,2020,27(4):485-491.
[8] KIM S,CHOI M C,JEONG J Y,et al.Serum exosomal miRNA-145 and miRNA-200c as promising biomarkers for preoperative diagnosis of ovarian carcinomas[J].J Cancer,2019,10(9):1958-1967.
[9] 叶宁珍,赵绍杰,王高莹,等.外泌体miRNA在妇产科疾病中的研究进展[J].南京医科大学学报(自然科学版),2021,41(6):932-936.
[10] HUANG X,YAN Y,GUI A,et al.A Regulatory loop involving miR-200c and NF-κB modulates mortalin expression and increases cisplatin sensitivity in an ovarian cancer cell line model[J].Int J Mol Sci,2022,23(23):15300-15315.
[11] VESCARELLI E,GERINI G,MEGIORNI F,et al.MiR-200c sensitizes olaparib-resistant ovarian cancer cells by targeting neuropilin 1[J].J Exp Clin Cancer Res,2020,39(1):3-15.
[12] SUNDARARAJAN V,BURK U C,BAJDAK-RUSINEK K.Revisiting the miR-200 family:a clan of five siblings with essential roles in development and disease[J].Biomolecules,2022,12(6):781-806.
[13] FERNÁNDEZ-PALANCA P,PAYO-SERAFÍN T,FONDEVILA F,et al.Neuropilin-1 as a potential biomarker of prognosis and invasive-related parameters in liver and colorectal cancer:a systematic review and meta-analysis of human studies[J].Cancers(Basel),2022,14(14):3455-3477.
[14] 李婧,崔自明,陈雅卓,等.神经纤毛蛋白1在卵巢癌组织标本中的表达及临床意义[J].中国组织化学与细胞化学杂志,2021,30(1):59-64,74.
[15] CHEN C,HU Y,LI L.NRP1 is targeted by miR-130a and miR-130b,and is associated with multidrug resistance in epithelial ovarian cancer based on integrated gene network analysis[J].Mol Med Rep,2016,13(1):188-196.
[16] PRAT J,FIGO Committee on Gynecologic Oncology.Staging classification for cancer of the ovary,fallopian tube,and peritoneum[J].Int J Gynaecol Obstet,2014,124(1):1-5.
[17] ARMSTRONG D K,ALVAREZ R D,BAKKUM-GAMEZ J N,et al.Ovarian Cancer,Version 2.2020,NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw,2021,19(2):191-226.
[18] CUI J,WANG H,ZHANG X,et al.Exosomal miR-200c suppresses chemoresistance of docetaxel in tongue squamous cell carcinoma by suppressing TUBB3 and PPP2R1B[J].Aging(Albany NY),2020,12(8):6756-6773.
[19] YANG C,LI H,ZHANG T,et al.miR-200c overexpression inhibits the invasion and tumorigenicity of epithelial ovarian cancer cells by suppressing lncRNA HOTAIR in mice[J].J Cell Biochem,2020,121(2):1514-1523.
[20] MENG X,MÜLLER V,MILDE-LANGOSCH K,et al.Diagnostic and prognostic relevance of circulating exosomal miR-373,miR-200a,miR-200b and miR-200c in patients with epithelial ovarian cancer[J].Oncotarget,2016,7(13):16923-16935. |